Vital Signs - NGS Dx: The Future of Sequencing in the Clinical Laboratory

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on December 6, 2010, provides a strategic overview of key issues and trends relating to next-generation sequencing. Additionally, a company spotlight is provided for GenturaDx, a company who has an exclusive license to more than 100 patents for assays, which should allow the company to develop an incredibly broad and robust menu of tests. Reimbursement and regulatory news from the FDA is also provided for the week of November 15, 2010.

Table of Contents

Vital Signs - NGS Dx: The Future of Sequencing in the Clinical LaboratoryVital Signs: 6 Dec 2010This week's issue:




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 07-Nov-17

Region : North America

Release Date : 06-Nov-17

Region : North America

Release Date : 31-Oct-17

Region : North America

Release Date : 30-Oct-17

Region : North America

Release Date : 25-Oct-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.